Literature DB >> 22331030

Chronic migraine--classification, characteristics and treatment.

Hans-Christoph Diener1, David W Dodick, Peter J Goadsby, Richard B Lipton, Jes Olesen, Stephen D Silberstein.   

Abstract

According to the revised 2nd Edition of the International Classification of Headache Disorders, primary headaches can be categorized as chronic or episodic; chronic migraine is defined as headaches in the absence of medication overuse, occurring on ≥15 days per month for ≥3 months, of which headaches on ≥8 days must fulfill the criteria for migraine without aura. Prevalence and incidence data for chronic migraine are still uncertain, owing to the heterogeneous definitions used to identify the condition in population-based studies over the past two decades. Chronic migraine is severely disabling and difficult to manage, as affected patients experience substantially more-frequent headaches, comorbid pain and affective disorders, and fewer pain-free intervals, than do those with episodic migraine. Data on the treatment of chronic migraine are scarce because most migraine-prevention trials excluded patients who had headaches for ≥15 days per month. Despite this lack of reliable data, a wealth of expert opinion and a few evidence-based treatment options are available for managing chronic migraine. Trial data are available for topiramate and botulinum toxin type A, and expert opinion suggests that conventional preventive therapy for episodic migraine may also be useful. This Review discusses the evolution of our understanding of chronic migraine, including its epidemiology, pathophysiology, clinical characteristics and treatment options.

Entities:  

Mesh:

Year:  2012        PMID: 22331030     DOI: 10.1038/nrneurol.2012.13

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  85 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 4.  Animal models of migraine: looking at the component parts of a complex disorder.

Authors:  A Bergerot; P R Holland; S Akerman; T Bartsch; A H Ahn; A MaassenVanDenBrink; U Reuter; C Tassorelli; J Schoenen; D D Mitsikostas; A M J M van den Maagdenberg; P J Goadsby
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

5.  Topiramate in the treatment of chronic migraine.

Authors:  M Silvestrini; M Bartolini; M Coccia; R Baruffaldi; R Taffi; L Provinciali
Journal:  Cephalalgia       Date:  2003-10       Impact factor: 6.292

6.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

Review 7.  Overuse of acute migraine medications and migraine chronification.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2009-08

8.  Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.

Authors:  Marcelo E Bigal; Daniel Serrano; Michael Reed; Richard B Lipton
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

9.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  32 in total

1.  The altered right frontoparietal network functional connectivity in migraine and the modulation effect of treatment.

Authors:  Zhengjie Li; Lei Lan; Fang Zeng; Nikos Makris; Jiwon Hwang; Taipin Guo; Feng Wu; Yujie Gao; Mingkai Dong; Mailan Liu; Jie Yang; Ying Li; Qiyong Gong; Sharon Sun; Fanrong Liang; Jian Kong
Journal:  Cephalalgia       Date:  2016-07-11       Impact factor: 6.292

Review 2.  Animal models of chronic migraine.

Authors:  Robin James Storer; Weera Supronsinchai; Anan Srikiatkhachorn
Journal:  Curr Pain Headache Rep       Date:  2015-01

3.  Non-invasive dural stimulation in mice: A novel preclinical model of migraine.

Authors:  Carolina Christina Burgos-Vega; Lilyana D Quigley; Gabriela Trevisan Dos Santos; Flora Yan; Marina Asiedu; Blaine Jacobs; Marina Motina; Nida Safdar; Hayyan Yousuf; Amanda Avona; Theodore John Price; Greg Dussor
Journal:  Cephalalgia       Date:  2018-05-31       Impact factor: 6.292

4.  Cursing the darkness: reactions to fibromyalgia.

Authors:  Manfred Harth
Journal:  Pain Res Manag       Date:  2013 Mar-Apr       Impact factor: 3.037

Review 5.  Economic burden and costs of chronic migraine.

Authors:  Michel Lanteri-Minet
Journal:  Curr Pain Headache Rep       Date:  2014-01

6.  Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches.

Authors:  Veronica Villani; Luca Prosperini; Fulvio Palombini; Francesco Orzi; Giuliano Sette
Journal:  Neurol Sci       Date:  2017-03-10       Impact factor: 3.307

7.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 8.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 9.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

Review 10.  Animal Models of Chronic Migraine.

Authors:  Tse-Ming Chou; Shih-Pin Chen
Journal:  Curr Pain Headache Rep       Date:  2018-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.